3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Myelodysplastic Syndromes
3
Small Cell Lung Carcinoma
2
Rectal Neoplasms
2
Prostatic Neoplasms
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Lung Neoplasms
2
Vulvar Neoplasms
1
Vulvar Diseases
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Stomach Neoplasms
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoma, Primary Effusion
1
Lymphoma, B-Cell
1
Lymphoma, AIDS-Related
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Gastrointestinal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Small Cell
1
Carcinoma in Situ
1
Interventions
Peripheral Blood Stem Cell Transplantation
10
Azacitidine
10
fludarabine phosphate
8
Whole-Body Irradiation
8
Cyclosporine
7
ruxolitinib
6
Mycophenolic Acid
6
Busulfan
6
Methotrexate
5
Cyclophosphamide
5
fludarabine
4
Tacrolimus
4
Filgrastim
4
Cytarabine
4
Antilymphocyte Serum
3
Alemtuzumab
3
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
3
venetoclax
2
eprenetapopt
2
Stem Cell Transplantation
2
Sirolimus
2
Melphalan
2
Granulocyte Colony-Stimulating Factor
2
Gemcitabine
2
Docetaxel
2
Cord Blood Stem Cell Transplantation
2
tipifarnib
1
sonidegib
1
rucaparib
1
quizartinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Myeloproliferative Disorders
×
Electrocardiography
×
Clear all
NCT07387354
2026-03-16
MDS
Thomas Jefferson University
Phase 1/2
Not yet recruiting
25 enrolled